Compare Crispr Therapeutics AG (CRSP) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Hyatt Hotels Corporation — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Hyatt Hotels Corporation trades at $189.7 (market cap $17.86B). The key difference: Hyatt Hotels Corporation is far larger — about 3.6× Crispr Therapeutics AG's market cap, and Hyatt Hotels Corporation pays a 0.32% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | H | |
|---|---|---|
Market Cap | $4.97B | $17.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $202.09 |
52-Week Low | $44.34 | $135.01 |
Enterprise Value | $3.32B | $21.71B |
Dividend Yield | — | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Hyatt Hotels (H) trades at $184.72, down 3.36% in the last session, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported Q1 2026 EPS of $0.63, beating expectations, but faces profitability challenges with negative net income margins and ROE. Recent developments include expansion announcements and strategic investor presentations, while analyst consensus remains cautiously optimistic with a $198.20 price target.
Hyatt presents a growth opportunity through hotel expansion and premium positioning, but investors face risks from inconsistent profitability, rising debt levels, and economic sensitivity. The stock's valuation appears stretched with a P/E of 31.36, requiring strong execution on revenue growth and margin improvement to justify current levels amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
